News Snapshot:
SINGAPORE – The preliminary data for Pfizer’s new antiviral pill “sounds promising”, said the National Centre for Infectious Diseases (NCID), adding that it is waiting for further data to be released before considering the drug for use in Covid-19 patients here. The preliminary data has shown the drug was able to cut by 89 per cent the chances of hospitalisation or death in adults at risk of developing severe disease, said Pfizer on Nov 5. They include those who had mild-to-moderate symptoms within a five-day period, and are at risk of developing severe illness such as chronic lung disease, high...